← AI Companies
Novo Nordisk is a Danish pharmaceutical company focused on diabetes and obesity treatments with no direct involvement in the AI ecosystem.
- Share Price
- 271.50DKK
- Market Cap
- 178.15BUSD
- Revenue
- 49.66BUSD
- Net Income
- 16.85BUSD
- P/E (trailing)
- 10.7x
Financial data: Yahoo Finance, as of 11-Nov-2026
Price & Size
| Price |
271.50 DKK |
| Market Cap |
1.20T DKK |
| Shares Outstanding |
3.33B |
| Shares Float |
3.16B |
| 52w Low |
224.25 DKK |
| 52w High |
409.95 DKK |
| Avg Volume |
4.89M |
Valuation
| P/E (trailing) |
10.7x |
| P/E (forward) |
12.0x |
| P/B |
5.50x |
| Enterprise Value |
1.29T DKK |
| Book Value / Share |
49.40 DKK |
| PEG Ratio |
4.50x |
| P/S |
3.59x |
| EV / Revenue |
3.85x |
| EV / EBITDA |
7.08x |
Income
| Revenue |
333.65B DKK |
| Revenue / Share |
75.25 DKK |
| EBITDA |
181.56B DKK |
| Net Income |
113.18B DKK |
| EPS (trailing) |
25.49 DKK |
| EPS (forward) |
22.67 DKK |
Margins & Profitability
| Gross Margin |
83.3% |
| Operating Margin |
40.1% |
| Profit Margin |
33.9% |
| EBITDA Margin |
54.4% |
| Return on Equity |
58.4% |
| Return on Assets |
19.1% |
Growth
| Revenue Growth |
5.6% |
| Earnings Growth |
-15.8% |
Cash & Debt
| Total Cash |
46.35B DKK |
| Total Debt |
134.48B DKK |
| Free Cash Flow |
32.75B DKK |
| Operating Cash Flow |
127.33B DKK |
| Debt / Equity |
0.62x |
| Current Ratio |
0.84x |
| Quick Ratio |
0.63x |
Dividend
| Rate |
11.70 DKK |
| Yield |
4.3% |
| Payout Ratio |
45.9% |
| Ex-Date |
14-Aug-2026 |
Analyst Consensus
| Target (Mean) |
299.91 DKK |
| Target (Median) |
287.50 DKK |
| Target (High) |
448.00 DKK |
| Target (Low) |
221.00 DKK |
| Analysts' Rating |
Hold |
| # Analysts |
24 |
Identifiers
| ISIN | DK0062498333 |
| SEDOL | 7133608 |
Sentiment 58.0%
as of 11-Nov-2026
Sentiment is an AI (Grok) reading of market mood over the past 30 days: 0% very negative, 50% neutral, 100% very positive.
Positive drivers
Strong ongoing demand for Ozempic and Wegovy continued to drive revenue growth in Q3 2026 results. Expansion into new obesity treatment markets in Asia supported positive analyst revisions. Novo Nordisk maintained leadership in the GLP-1 segment amid rising global prescriptions.
Neutral / mixed
Regulatory reviews on long-term safety data created some uncertainty but no immediate restrictions. Currency fluctuations from DKK strength partially offset international sales gains. Market share gains were tempered by emerging competition from Eli Lilly's pipeline updates.
Negative drivers
Patent litigation risks in the US weighed on investor confidence during the period. Supply chain constraints led to temporary shortages and negative media coverage. Rising healthcare cost pressures prompted payer negotiations that capped pricing upside.
Bottom line
Sentiment remained mildly positive overall, supported by core product momentum but tempered by regulatory and competitive headwinds. The stock showed resilience within the broader healthcare sector.
Nasdaq CPH
DKK